
Anbio Biotechnology: Risky Valuation Concerns As COVID-Related Sales Decline
NNNN is currently pivoting from pandemic tests and expanding its assays into oncology, cardiovascular, hormonal, and infectious diseases. Their 2024 revenues increased YoY with gross margin improving as well, thanks to higher-margin assays and better …